Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.


OrganOx was spun out from the University of Oxford in April 2008 and has developed the world’s first normothermic liver perfusion device, the Metra, approved for storage and transportation of human livers prior to transplant.

The technology, which is also being developed for the normothermic perfusion of kidneys, has the potential to disrupt the transplant market, significantly increasing the supply of viable organs by overcoming several major limitations in existing methods. The 220-patient European clinical trial data was published in the prestigious academic journal Nature in Q2 2018.


Professors Constantin Coussios & Peter Friend

Constantin and Peter have been working together for more than 20 years on OrganOx’s proprietary normothermic organ perfusion technology – the metra. Since then, over 50 publications have supported the technology, demonstrating its advantages over conventional cold storage and cold perfusion technologies. To date, more than 1,000 metra supported liver transplants have been performed globally.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. He founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes.


Partner with us?

Get in touch